BLOG

Fierce-Biotech

Novellus becomes Fore Biotherapeutics as it completes pivot from diagnostics to precision oncology

NovellusDx started out as a diagnostics company but has been making moves toward becoming a cancer therapeutics biotech in recent months, picking up a BRAF drug from Daiichi Sankyo and raising $57 million to shepherd it through the clinic. Now, it’s wrapping its transformation up with a new name and a new CEO: Fore Biotherapeutics and Usama Malik, a former Immunomedics executive who orchestrated the company’s $21 billion buyout by Gilead.